Precision Oncology .

BREAKING NEWS - PRECISION ONCOLOGY BECOMES PRECISION FOR MEDICINE, ONCOLOGY AND RARE DISEASE FOLLOW OUR NEW SHOWCASE PAGE FOR THE LATEST IN COMPANY NEWS, RESEARCH AND PUBLICATIONS - @Precision For Medicine, Oncology and Rare Disease Precision is excited to announce that Precision Oncology has officially changed its name to Precision for Medicine, Oncology and Rare Disease. The new name reflects the expanded capabilities and global scale Precision for Medicine, Oncology and Rare Disease offers our valued clients: integrated clinical development operations, translational sciences, and clinical development planning. These comprehensive services, not found in traditional CROs, allow our clients to apply new advancements in science, target defined patient populations, and obtain deeper data-ultimately, accelerating the drug development pathway. With Precision for Medicine's acquisition of Agility Clinical, a CRO focused on rare disease and orphan therapies, we expanded our therapeutic focus to include rare disease, including rare cancers. Our new name signifies our renewed commitment, and we will continue our specialization in providing both oncology and rare disease-specific expertise and study teams.

网站

https://www.precisionmedicinegrp.com/pfmord

Precision Oncology .的外部链接

所属行业

制药业

规模

201-500 人

总部

Flemington，NJ

类型

私人持股

领域

Phase I-III Oncology Clinical Programs、Oncology Registry & Observational Cohort Studies、Medical Monitoring、Rescue Programs、Data Mgmt Services、Clinical Data Review、Regulatory Compliance and Submissions和Biomarker planning and services